**Analysis of contributory gut microbiota and lauric acid against necrotic enteritis in
Clostridium perfringens and *Eimeria* side-by-side challenge model**

Short title: The impact of *Clostridium perfringens* challenge on gut microbiota in chickens

Wen-Yuan Yang¹, Yuejia Lee¹, Hsinyi Lu¹, Chung-Hsi Chou², Chinling Wang^{1*}

¹ Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University,
P.O. Box 6100, Mississippi State, MS 39762, ² Zoonoses Research Center and School of
Veterinary Medicine, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei City,
106, Taiwan

*Corresponding author: cw57@msstate.edu

Abstract

Gut microbiota has been demonstrated to be involved in intestinal nutrition, defense, and immunity, as well as participating in disease progression. This study was to investigate gut microbiota changes in chickens challenged with *netB*-positive *Clostridium perfringens* strain 1 (CP1) and/or the predisposing *Eimeria* species (*Eimeria*). In addition, the effects of lauric acid, a medium-chain fatty acid (MCFA), on NE reduction and modulation of microbiota were evaluated. The results demonstrated that microbial communities in the jejunum were distinct from those in the cecum, and the microbial community change was more significant in jejunum. Challenge of CP1 in conjunction with *Eimeria* significantly reduced species diversity in jejunal microbiota, but cecal microbiota remained stable. In the jejunum, CP1 challenge increased the abundance of the genera of *Clostridium sensu stricto 1*, *Escherichia Shigella*, and *Weissella*, but significantly decreased the population of *Lactobacillus*. *Eimeria* infection on its own was unable to promote NE, demonstrating decrements of *Clostridium sensu stricto 1* and *Lactobacillus*. Co-infection with CP1 and *Eimeria* reproduced the majority of NE lesions with significant increment of *Clostridium sensu stricto 1* and reduction in *Lactobacillus*. The changes of these two taxa increased the severity of NE lesions. Further analyses of metagenomeSeq, STAMP, and LEfSe showed significant overgrowth of *Clostridium sensu stricto 1* was associated with NE and *Eimeria* infection than *C. perfringens* challenge alone. The supplementation of lauric acid did not reduce NE incidence and severity but decreased the relative abundance of *Escherichia Shigella*. In conclusion, significant overgrowth of *Clostridium sensu stricto 1* in the jejunum is the major microbiota contributory to NE. Controlling proliferation of this taxon in the jejunum should be the niche for developing effective strategies against NE.

38   Keywords: necrotic enteritis, *Clostridium perfringens*, *Eimeria*, lauric acid, microbiota

Introduction

Necrotic enteritis (NE) as the result of proliferations of *Clostridium perfringens* (*C. perfringens*) type A and their associated toxins in the small intestine of chickens is a devastating enteric disease, characterized by sudden diarrhea, unexpected mortality, and mucosal necrosis [1, 2]. Up to 37% of commercial broiler flocks is estimated to be affected by this disease, and it has contributed to the losses of 6 billion dollars in the global poultry industry [3, 4]. In recent decades, *C. perfringens*-associated NE in poultry has been well-controlled by in-feed antimicrobial growth promoters (AGPs) [5]. However, the emergence of antibiotic-resistant bacteria from animals and the potential threat of transmission to humans has led to bans on using AGPs in many countries [6, 7]. Following the withdrawal of AGPs from poultry feed, NE has re-emerged as a significant disease to the poultry industry [8-11].

Gut microbiota is one of the central defense components in the gastrointestinal tract against enteric pathogens, which works by modulating host responses to limit the colonization of pathogens [12]. Interactions between gut microbiota and the host could influence intestinal morphology, physiology, and immunity [13]. Recently, gut microbiota has been demonstrated to regulate intestinal gene expression [14] and T cell-mediated immunity [15] as well as to accelerate the maturation of the gut immune system [16]. Conversely, a growing number of studies have observed gut microbial shifts in enteric diseases, considering that gut microbiota plays a role in the progress of disease development. Similar results were also represented in NE induction models, proposing that the disturbance of gut microbiota interacts with the host, subsequently promoting the development of NE [17-20]. In the case of human necrotizing enterocolitis, an enteric disease in infants associated with *C. perfringens* [21], a recent study found that *Bacteroides dorei*, an opportunist pathogenic bacterium in anaerobic infections, was

associated with an increased mortality of this disease [22]. Furthermore, several studies have demonstrated that the increment of bacteria belong to a genus of *Escherichia-Shigella* was associated with *C. perfringens* infection [5, 20]. This evidence raised the possibility that certain microbes or microbiota in the gut may contribute to the virulence or development of enteric disease in chickens, particularly for NE.

The removal of AGPs drove the poultry industry to search for an alternative in prevention to decrease the incidence of NE. Probiotics, prebiotics, organic acids, plant extracts, essential oils, and enzymes arose in response to this demand, but the efficacy of those on NE reduction were variable and inconsistent [23, 24]. However, a medium-chain fatty acid (MCFA), lauric acid, was found to have strong *in vitro* antimicrobial activity against gram-positive organisms [25-27] and *C. perfringens* [28, 29]. In an *in vivo* trial, lauric acid with butyric acid demonstrated the lowest incidence and severity of NE compared to other treatments [29]. However, this promising result did not promote more applications of lauric acid against NE, and the interaction of lauric acid with gut microbiota was not even addressed. The evaluation of its modulation effect on NE reduction and gut microbiota simultaneously would be valuable in exploring specific microbial community contributory to NE.

Although *C. perfringens* is the causative etiological agent of NE, it is evident that other predisposing factors are required for NE induction [10, 30-32]. Even though gut microbiota has been suggested to be involved in the progress of NE development [33, 34], association between microbiota profile and NE development have not been well elucidated. Most studies intensively focused on changes of microbial communities in the ileum or cecum where higher quantity of microbes or/and more diverse microbial compositions were harbored; however, most results were inconclusive [17-19, 35, 36]. Inversely, microbiota in the jejunum, which serve as the

primary site for colonization of *C. perfringens* and development of NE [33], was seldom evaluated. In the present study, we investigated gut microbiota targeting NE cases and in chickens with side-by-side treatments with the causative pathogen and parasitic predisposing factor, *Eimeria*, and expected to unveil the contributory microbe or microbiota to NE. The effects of lauric acid on NE reduction and modulation of microbiota were also examined to confer the alternative intervention to prevent and control NE.

Materials and methods

Ethics statement

All procedures for the care, housing and treatment of chickens were approved by the Institutional Animal Care and Use Committee at Mississippi State University (IACUC 16-439).

Chicken, diet, and experimental design

A total of 50 male and female one-day-old unvaccinated broiler chicks (Cobb strain) were obtained from a commercial hatchery. Chicks were inspected on receiving to ensure their healthy status and randomly allotted to 5 groups, studying the NE incidence and gut microbiota after challenge of *netB*-positive *C. perfringens* (A group: CP1), co-infection with *netB*-positive *C. perfringens* and multi-species *Eimeria* (B group: CP1+*Eimeria*), addition of lauric acid to feed chickens co-infected with *netB*-positive *C. perfringens* and multi-species *Eimeria* (C group: CP1+*Eimeria*+LA), inoculation of multi-species *Eimeria* (D group: *Eimeria*), and no treatment (E group: CTL).

Chicks in groups were placed in separate temperature-controlled iron tanks with nets in the floor-pen facility and lined with fresh litter. Throughout the 19-day study period, wheat-based

diets prepared based on the formula by Branton et al. [37] were offered for the first 7 days, and then the rations were replaced by fishmeal diets (wheat-based diets containing 50% fishmeal) obtained from the 1:1 mixture of wheat-based diet with fishmeal 60 N (Seven Springs Farm, Check, Virginia, USA), containing minimal 60% crude protein from days 8 until the end of the study. For the lauric acid supplementing group, 400 mg of lauric acid powder (Fisher Scientific, Pittsburgh, Pennsylvania, USA) was added into 1 kg of wheat-based diet or fishmeal diet to form the final ration for chickens from day 8 onward [29].

Co-infection with *netB*-positive *C. perfringens* (CP1) and multi-species *Eimeria* was applied to induce NE according to our previous studies. The success of reproducing NE was determined by clinical signs and intestinal lesion scores reaching 2 or more. In brief, chickens in the co-infection group were given a single gavage of coccidial inoculum at day 10, followed by oral administration of 3 ml CP1 inoculum with average 2.5×10^8 colony-forming units (CFU)/ml at day 15 for 4 consecutive days with a frequency of 3 times daily. For a single challenge of CP1 or *Eimeria*, the same methodology and time points were conducted as in the co-infection group. All chickens were inspected on a daily basis and humanely euthanized at day 19 by carbon dioxide. Dead chickens not resulting from NE were excluded from the trial after necropsy. The experimental trial was reviewed and approved by the Mississippi State University Institutional Animal Care and Use Committee.

Challenge strain and inoculum preparation

Anticoccidial live vaccine containing live oocysts of *E. acervulina*, *E. maxima*, *E. maxima* MFP, *E. mivati*, and *E. tenella* was used as a disposing factor. The vaccine bottle contained 10,000 doses of oocysts in an unspecified proportion of *Eimeria* species. A ten-fold dose of vaccine was

prepared then applied on *Eimeria*-treated and co-infection groups. *C. perfringens*, a clinical NE strain designated as CP1 obtained from Dr. John F. Prescott (Ontario Agricultural College, University of Guelph, Canada), was used to challenge chickens. This strain was characterized as *netB*-positive Type A and used to reproduce NE in a number of experiments [38-41]. CP1 was cultured on blood agar plates and incubated anaerobically at 37°C for overnight. A single colony was in turn transferred into 3 ml of fluid thioglycollate (FTG) medium (Himedia, Mumbai, Maharashtra, India) at 37°C for overnight. Thereafter, the bacterial suspension was inoculated into fresh FTG broth at a ratio of 1:10 and incubated at 37°C for 15, 19, and 23 hours, respectively. The whole broth cultures were used to induce NE based on the evidence that clostridia with toxins produce more severe disease than using cells alone [38]. The bacterial concentration (CFU/ml) of inoculum was calculated by plate counting using Brain Heart Infusion agar (Sigma-Aldrich, St. Louis, Missouri, USA), followed by anaerobic incubation at 37°C for 16 hours.

Sample collection and lesion scoring

Three chickens per group were randomly selected to collect fecal contents from the jejunum (AJ, BJ, CJ, DJ, and EJ) and cecum (AC, BC, CC, DC, and EC). Among three CP1-challenged groups (A, B, and C), chickens suffering NE (lesion score ≥ 2) were preferentially collected. Then, the remaining chickens were sampled randomly to reach a quantity of 3. One percent of 2-mercaptoethanol (Sigma-Aldrich) in PBS was used to wash fecal contents, and samples were immediately frozen at -80°C. The intestinal tissues (duodenum to ileum) were inspected for NE lesions and scored following the criteria described by Keyburn [42], with a range of 0 (no gross lesions), 1 (congested intestinal mucosa), 2 (small focal necrosis or ulceration; one to five foci),

3 (focal necrosis or ulceration; 6 to 15 foci), and 4 (focal necrosis or ulceration; 16 or more foci). Chickens with lesion scores reaching 2 or higher were identified as NE cases, and the highest score in their small intestinal sections (duodenum, jejunum, and ileum) was recorded as the final score of NE.

DNA extraction

Total genomic DNA was isolated from approximately 250 mg of fecal contents using the MOBIO PowerFecal® DNA Isolation Kit (Mobio, Germantown, Maryland, USA) following the manufacturer's protocol with some modifications. After adding bead solution and lysis buffer, the mixture was heated in a water bath at 65°C for 30 minutes followed by 5 minutes of vortexing. The concentration and quality of harvested DNA were determined by NanoDrop™ One Microvolume UV-Vis Spectrophotometer (Fisher Scientific) and visualized on 0.8% agarose gel (BD Biosciences, San Jose, California, USA). Afterward, genomic DNA was stored at -20°C until further analysis.

16S rRNA library preparation and sequencing

The variable V3-V4 region of the 16S rRNA gene was PCR-amplified in 25-μl reaction mixtures, containing 12.5 μl Clontech Labs 3P CLONEAMP HIFI PCR PREMIX (Fisher Scientific), 1 μl of each 10-μm Illumina primer (forward primer-5'CCTACGGGNGGCWGCAG 3' and reverse primer-5' GACTACHVGGGTATCTAATCC 3') with standard adapter sequences, and 1 μl of DNA template. The PCR conditions started with an initial denaturation step at 95°C for 3 minutes, followed by 25 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, and a final extension step at 72°C for 5 minutes on Applied Biosystems GeneAmp PCR

System 9700 (Applied Biosystems Inc., Foster City, California, USA). The amplicons were cleaned up by Monarch® DNA Gel Extraction Kit (New England Biolabs, Ipswich, Massachusetts, USA). Subsequently, an index PCR was performed by using Nextera XT Index Kit (Illumina, San Diego, California, USA) to attach a unique 8-bp barcode sequence to the adapters. The applied 25-µl reaction was composed of 12.5 µl KAPA HiFi HotStart Ready Mix (Kapa Biosystems, Wilmington, Massachusetts, USA), 2.5µl of each index primer, and 1 µl of 16S rRNA amplicon and reaction conditions were as follows: 95°C for 3 minutes, 8 cycles of 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, and 72°C for 5 minutes on Mastercycler® pro (Eppendorf AG, Hamburg, Germany). The PCR products were purified using Agencourt AMPure XP beads (Beckman Coulter, Indianapolis, Indiana, USA), and the size and concentration were determined by Bioanalyzer with DNA 1000 chip (Agilent, Santa Clara, California, USA) and Qubit® 2.0 Fluorometer with Qubit™ dsDNA HS Assay Kit (Fisher Scientific). Those libraries were normalized and pooled to one tube with the final concentration of 10 pM. Samples were thereafter sequenced on the MiSeq® System using Illumina MiSeq Reagent Kit v3 (2×300 bp paired-end run).

Sequence processing and data analysis

Paired-end sequences were merged by means of fast length adjustment of short reads (FLASH) v1.2.11 [43] after trimming of primer and adapter sequences. Reads were de-multiplexed and filtered by Quantitative Insights into Microbial Ecology (Qiime) software v1.9.1 [44], meeting the default quality criteria and a threshold phred quality score of $Q \geq 20$. Chimeric sequences were filtered out using the UCHIME algorithm [45]. The pick-up of operational taxonomic units (OTUs) was performed at 97% similarity by the UPARSE algorithm [46] in USEARCH [47].

The OTUs were further subjected to the taxonomy-based analysis by RDP Classifier v2.11 with a cut-off of 80% [48] using the Silva v128 database. Differential abundance of OTU among treatments was evaluated by metagenomeSeq. The clustered OTUs and taxa information were used for diversity and statistical analyses by Qiime v1.9.1 and R package v.3.3.1 (<http://www.R-project.org/>). Differences of taxonomic profiles between groups were compared using Statistical Analysis Metagenomic Profiles (STAMP) software [49] v2.1.3 with Welch's t-test. Furthermore, LEfSe (linear discriminant analysis effect size) from the LEfSe tool (<http://huttenhower.sph.harvard.edu/lefse/>), an algorithm for high-dimensional class comparisons between biological conditions, was used to determine the significant feature taxa between groups or intestinal location. It emphasizes statistical significance, biological consistency, and effect relevance and allows researchers to identify differentially abundant features that are also consistent with biologically meaningful categories [50]. The Kruskal-Wallis rank sum test was included in LEfSe analysis to detect significantly different abundances and performed LDA scores to estimate the effect size (threshold: ≥ 4).

Results

NE reproduction and effects of lauric acid as an alternative prevention

Six of the NE cases were identified in three CP1-challenged groups (**Table 1**). They showed different degrees of characteristic gross lesions in small intestinal tissues. The most severe lesions were found in the jejunum, between its proximal end and Meckel's diverticulum. Under co-infection with CP1 and *Eimeria*, the incidence and severity of NE increased. No NE mortality was noticed. Statistically significant differences of lesion score (LS) were determined between three CP1-challenged groups (A, B, and C) and the control counterpart ($p \leq 0.05$). The co-infection groups (B and C) demonstrated a highly significant difference ($p \leq 0.01$). However, the supplementation of lauric acid did not reduce the incidence and severity which were similar to the NE positive control group.

Table 1. NE frequency and mean lesion score by groups

Group	Treatment	NE lesion score					Subtotal	Lesion score	NE case
		0	1	2	3	4			
A	CP1	0	9	1	0	0	10	1.11 ± 0.31^a	1
B	CP1+ <i>Eimeria</i>	0	8	0	1	1	10	1.50 ± 1.02^a	2
C	CP1+ <i>Eimeria</i> +LA	0	7	1	1	1	10	1.60 ± 1.02^a	3
D	<i>Eimeria</i>	-	-	-	-	-	10	-	0
E	CTL	5	4	0	0	0	9	0.44 ± 0.50^b	0

LA lauric acid; NE necrotic enteritis; CTL: control group.

NE case: lesion score reaching 2 or above.

One chick in CTL was misclassified during the trial and excluded.

Dissimilar letters indicate a significant difference at a level of $\alpha=0.05$.

Metadata and sequencing

A total of 11,191,102 sequence reads with an average length of 453 ± 5 base pairs were obtained from 30 samples, including 15 jejunal samples (3 samples per group in AJ, BJ, CJ, DJ, and EJ) and 15 cecal samples (3 samples per group in AC, BC, CC, DC, and EC). The sequences were filtered and further clustered into OTU using a cut-off of 97% similarity. The estimate of Good's coverage reached 98% for all the jejunal and cecal samples. The rarefaction curve demonstrated that the sequencing depth was adequate to cover the bacterial diversity in the jejunal and cecal samples (**Figure S1**).

Normal microbial composition in the jejunum and cecum

Firmicutes (92.1% of relative abundance) was the most dominant phylum in the jejunum, followed by *Cyanobacteria* (2.2%) and *Proteobacteria* (2.1%), *Bacteroidetes* (1.9%), and *Actinobacteria* (1.7%). On the contrary, the phylum of *Bacteroidetes* (75.5%) predominated in the cecum, followed by *Firmicutes* (19.8%) and *Proteobacteria* (4.7%) (**Figure 1A**). At the genus level, jejunal contents were dominated by *Lactobacillus* (41.2% of relative abundance) and *Clostridium sensu stricto 1* (39.1%), followed by other unclassified genus (8.7%), *Weissella* (3.6%), *Enterococcus* (1.9%), *Escherichia Shigella* (1.8%), and *Staphylococcus* (1.6%). *Bacteroides* (75.5%) was the most abundant genus in the cecum, followed by other unclassified genus (17.2%), *Escherichia Shigella* (3.1%), *Eisenbergiella* (1.7%), and *Anaerotruncus* (1.5%) (**Figure 1B**). The genera of *Lactobacillus*, *Clostridium sensu stricto 1*, *Weissella*, *Enterococcus*, *Staphylococcus*, and *Bifidobacterium* in the jejunum exhibited significant difference in abundance compared to those in the cecum. Cecal microbiota contained significantly higher abundance of *Bacteroides* and *Proteus* (Welch's t test, $p < 0.05$; **Figure S2**).

Changes of microbial communities in response to treatments

In the jejunum, challenge of CP1 increased the relative abundance of the genera of *Clostridium sensu stricto 1* (54.75%), *Escherichia Shigella* (9.57%), and *Weissella* (4.99%) but significantly decreased the population of *Lactobacillus* (25.44%) (**Figure 2**). The inoculation of *Eimeria* to chickens significantly increased the relative abundance of *Weissella* (16.01%) and *Staphylococcus* (6.51%), but decreased the amount of *Lactobacillus* (30.66%) and *Clostridium sensu stricto 1* (27.69%). Co-infection with CP1 and *Eimeria* led to significant increment of *Clostridium sensu stricto 1* (71.89%), increased relative abundance of *Escherichia Shigella* (4.68%), but the decrements of *Lactobacillus* (16.99%), *Weissella* (0.44%) and *Staphylococcus* (0.40%). In the cecum, different treatments did not promote significant difference of taxa abundance between groups with an exception of *Eisenbergiella*, significantly increased in co-infection group. However, challenge of CP1 and co-infection of CP1 and *Eimeria* still promoted cecal increments of *Clostridium sensu stricto 1* (the relative abundance of this taxon in groups challenging with CP1, CP1 and *Eimeria*, and control was 0.75%, 1.99%, and 0.02%).

285 (A)

286
287 (B)

288

289 (C)

290
291

292 (D)

293
294

(E)

(F)

Figure 2. Differential abundance of genera between groups by metagenomeSeq. (A)

Lactobacillus; (B) *Clostridium sensu stricto 1*; (C) *Weissella*; (D) *Staphylococcus*; (E)

Escherichia Shigella; (F) *Eisenbergiella*. * $p \leq 0.05$ and ** $p \leq 0.01$.

Microbial diversities in response to treatments

In jejunal microbiota, challenge of CP1 (AJ) and co-infection with CP1 and *Eimeria* (BJ)

reduced species richness and evenness, but the infection of *Eimeria* (DJ) exerted counter results.

Addition of lauric acid into co-infection group (CJ) exacerbated the reduction observed in BJ

group. However, no apparent effect was noted on cecal microbiota following above treatments

(Figure S3 and Figure 3). Analysis of alpha diversity by Shannon index further demonstrated

that challenge of CP1 in conjunction with *Eimeria* infection significantly reduced species

diversity in jejunal microbiota. The 16S rRNA gene survey by principal coordinate analysis

(PCoA) and principal component analysis (PCA) showed a distinct separation of two community profiles between the jejunal and cecal microbiota. Cluster and heat map analyses exhibited distinct classifications and microbial compositions between the jejunum and cecum, coinciding with observations on PCoA and PCA (**Figure 4**). Additionally, the results of PCoA and PCA also depicted the differential diversity between the CP1-challenged (group AJ, BJ and CJ), *Eimeria*-infected (DJ), and control (EJ) groups in jejunal microbiota, showing that challenge of CP1 shared similar microbial community structures with co-infection with CP1 and *Eimeria*. However, cecal groups with CP1 treatments did not display cluster phenomenon as jejunal groups displayed in PCoA. PCA with hierarchical clustering further reflected that *Clostridium sensu stricto 1* was contributory to the similarity of NE assemblage, and the genera of *Lactobacillus*, *Weissella*, and *Staphylococcus* contributed to discrepant community structures in *Eimeria*-treated and control groups in the jejunum. On the other hand, *Bacteroidetes* was the main genus contributing to the distinct separation between jejunal and cecal groups (**Figure 5**).

(A)

(C)

Figure 3. Comparison of microbial diversity between groups in jejunum and cecum using different measures of alpha diversity. (A) Shannon index, (B) Simpson index (C), abundance-based coverage estimator (ACE) index, and (D) Chao1 index. Results are shown as mean $\pm$ SEM. Kruskal-Wallis test: * $p \leq 0.05$, ** $p \leq 0.01$, and *** $p \leq 0.001$.

(A)

(B)

(C)

(D)

Figure 4. Comparison of the compositions and similarities of jejunal and cecal microbiota with different treatments. (A) Weighted Unifrac principal coordinate analysis (PCoA); (B) principal component analysis (PCA); (C) cluster analysis by unweighted paired-group method using

arithmetic means (UPGMA) using unweighted Unifrac distance; (D) heat map analysis at the genus level.

Figure 5. Principal component analysis and hierarchical clustering of contributory genus to NE assemblage (in red circle) and to the dissimilarity between groups.

Microbial community structure and taxa contributory to NE

Analysis of jejunal microbiota in NE cases revealed that *Clostridium sensu stricto 1*, to which causative *C. perfringens* belongs, was the most dominant genus, followed by *Lactobacillus*, *Weissella*, *Escherichia Shigella*, *Staphylococcus*, and others. Accompanying the elevation of NE severity, the relative abundance of *Clostridium sensu stricto 1* increased (relative abundance $\geq$ 75% in LS4 compared to 50-75% in LS2 and LS3). Conversely, the population of *Lactobacillus* decreased while the lesion score was elevated. The relative amount of *Escherichia Shigella* was

variable in NE cases, presenting higher abundance after CP1 challenge but low population following co-infection with CP1 and *Eimeria*. (**Figure 1C**).

Heat map analysis exhibited that NE cases harbored the similar microbial community profile.

Clostridium sensu stricto 1 and *C. perfringens* were consistently presented and abundant taxa in jejunum (**Figure 6**). Opposite low abundance of *Lactobacillus* was noted. However, only the

increment of *Clostridium sensu stricto 1* but not *C. perfringens* (data not shown) demonstrated

significance on NE by metagenomeSeq (**Figure 2B**). Using Welch's t-test, jejunal groups further

showed that CP1 in conjunction with *Eimeria* increased significantly *Clostridium sensu stricto 1*

and *C. perfringens* when compared to the control (**Figure S4**; $p < 0.05$), whereas challenge of

CP1 alone did not lead to significant increase of these taxa. Differential abundant phylotypes

between different treatments in jejunum were further evaluated by LefSe using the LDA score of

4. This threshold guarantees that the meaningful taxa is compared and eliminates most of rare

taxa. LefSe demonstrated similar results as Welch's test that challenge of CP1 unable to yield a

significantly higher amount of *Clostridium sensu stricto 1* and *C. perfringens*. However,

significant differences were displayed when CP1 co-infected with *Eimeria* (**Figure 7**). No

differential taxon was found in cecal groups (AC, BC, CC, HDC, and EC) while Welch's t-test

and LefSe were applied.

388 (A)

389
390

391 (B)

392
393

(C)

Figure 6. Heat map analysis of contributory taxa to NE at the genus level in jejunal (A) and

cecal (B) samples. (C) Heat map of gut bacteria with the relative abundance of OTUS by z score

and represented bacterial taxa information, including phylum, family, genus, and species. Top 26 taxa was shown.

(A)

405 (B)

Figure 7. LEfSe identified the most differentially abundant clades at all taxonomic levels

between jejunal groups using the LDA score of 4. Differentially abundant taxa in group BJ versus EJ (A) and CJ versus EJ (B).

Comparison of gut metagenomes in co-infected chickens with and without lauric acid

Addition of lauric acid increased the relative abundance of *Clostridium sensu stricto 1* and *Weissella* but decreased the relative amount of *Escherichia Shigella* in the jejunum compared to the co-infection group without supplementing lauric acid. Nonetheless, no significance was detected in this comparison. In addition, supplementation of lauric acid did not apparently affect the cecal microbiota between these two groups.

Discussion

By exploring microbial composition in normal chickens, the major microbial genera in the jejunum were *Lactobacillus* and *Clostridium sensu stricto* 1, followed by other unclassified bacteria, *Weissella*, *Enterococcus*, *Escherichia Shigella*, and *Staphylococcus*. *Bacteroides* was the most abundant group in the cecum, and the remaining taxa were sequentially other unclassified bacteria, *Escherichia Shigella*, *Eisenbergiella*, and *Anaerotruncus*. Side by side treatments of *C. perfringens* and *Eimeria* altered microbial community compositions, significantly in jejunal microbiota. In this study, challenge of CP1 increased the abundance of *Clostridium sensu stricto* 1, *Escherichia Shigella*, and *Weissella* in the jejunum, but significantly decreased the population of *Lactobacillus*. Infection of *Eimeria* significantly increased the abundance of *Weissella* and *Staphylococcus*, but decreased the amount of *Lactobacillus* and *Clostridium sensu stricto* 1. Co-infection with *C. perfringens* and *Eimeria* led to significant increment of *Clostridium sensu stricto* 1, increased abundance of *Escherichia Shigella*, but decrements of *Lactobacillus*, *Weissella* and *Staphylococcus*. Specifically, it decreases the α -diversity index of the small intestinal microbial community, promoting single dominance of *Clostridium sensu stricto* 1 reaching the relative abundance to 71.89%. On the other hand, six NE cases shared similar microbial community profile observed in PCA, indicating there exists a certain microbiota contributory to the disease. With more NE severity, higher relative abundance of *Clostridium sensu stricto* 1 but lower relative amount of *Lactobacillus* in jejunal microbiota was noted.

Several studies has been shown *C. perfringens* challenge decreased the population of *Lactobacillus* in ileum [20, 51]. Lactobacilli are known as lactic acid producing bacteria and shown to have protection at intestinal barrier by competition with pathogens. They are also able

to induce immunomodulation and ferment carbohydrates into lactic acids that lower the pH of the intestinal environment to inhibit growth of acid-sensitive pathogenic bacteria [52, 53]. Therefore, suppression of lactobacilli is regularly considered beneficial to growth and colonization of enteric pathogen. This study first demonstrated the decrement of lactobacilli in jejunum following challenge of *C. perfringens* alone and in conjunction with *Eimeria*. The change of this taxon following the NE severity indicates that decrement of *Lactobacillus* may play a role in the development of NE. In addition, the increased abundance of *Escherichia Shigella* was also observed after the challenge of *C. perfringens* and co-infection with *C. perfringens* and *Eimeria*. This genus includes enteric pathogens, which can colonize in the intestines of both humans and chickens, consequently triggering specific diseases [54]. Some studies indicated that the increment of *Escherichia Shigella* in ileum was correlate with NE [55, 56]. Nevertheless, our study found that *C. perfringens* challenge could increase the abundance of *Escherichia Shigella* but the increment was not in accordance with NE occurrence. Furthermore, the reduction of this taxa abundance was noticed in lauric acid supplementing group which has higher number of NE cases. Those finding reflected a contradiction for this genus participating in NE development. Last but not least, a reduced abundance of *Weissella* in the jejunum of NE afflicted chickens was also noted. Another study reported similar result in cecal micorbiota after *C. perfringens* challenge [18]. *Weissella* are lactic acid bacteria and belong to the family of the *Leuconostocaceae*. They harbor probiotic properties and can generate several products with prebiotic potential [57]. It may interact with *C. perfringens* as other lactic acid bacteria, but its role in NE development is unclear. More studies will be needed to elucidate the relationship between *Weissella* and NE.

In current study, significant overgrowth of *Clostridium sensu stricto 1* was associated with NE and the infection of *Eimeria* precedent to challenge of *C. perfringens* exerted synergistic effects on the overrepresentation. This correlation was consistently demonstrated by analyses of metagenomeSeq, STAMP, and LEfSe. The STAMP and LEfSe further showed *C. perfringens* was significantly overrepresented in NE groups. However, such significance was not identified by metagenomeSeq when *C. perfringens* was targeted. This result indicates that, in addition to *C. perfringens*, other bacteria under the same genus of *Clostridium sensu stricto 1* also played a role in contributing to the development of disease. The *Clostridium* genus is well-classified into 19 clusters by phylogenetic analysis [58]. *Clostridium sensu stricto* are grouped around the type species *Clostridium butyricum* and belong to the *Clostridium* cluster 1 within the *Clostridiaceae* family [59]. *Clostridium sensu stricto 1* contains *C. perfringens* and other real *Clostridium* species. Their members are generally perceived as pathogenic [60] as well as interpreted as an indicator of a less healthy microbiota [61]. This suggestion coincides with our finding that *C. perfringens* challenge on its own is not capable of causing significant abundance of *Clostridium sensu stricto 1* and unable to produce more NE case observed. Future research is recommended to clarify the role of other members of *Clostridium sensu stricto 1* in the pathogenesis of NE.

Single infection of *Eimeria* could not produce NE in the present study. The treatment reduced the relative abundance of *Clostridium sensu stricto 1* and *Lactobacillus*, but significantly increased *Weissella* and *Staphylococcus* in jejunal microbiota. *Eimeria* infection has been shown to provide nutrients for *C. perfringens* to grow and cause physical damage to gut epithelium, thus facilitating the colonization and proliferation of *C. perfringens* [8, 62, 63]. However, the inoculation of *Eimeria* into normal chickens did not elicit overgrowth of *Clostridium sensu stricto 1* and *C. perfringens* except challenging with exogenous *C. perfringens*. In contrast,

challenge of *C. perfringens* alone and in conjunction with *Eimeria* both promote proliferation of *Clostridium sensu stricto* 1 and NE case. This indicates that the amount of commensal *C. perfringens* in the jejunum under *Eimeria* infection is not sufficient to reach the significant abundance of *Clostridium sensu stricto* 1 or *C. perfringens*, subsequently promoting the occurrence of NE. Therefore, it is reasonable to suggest that the quantity of *Clostridium sensu stricto* 1 or *C. perfringens* in jejunum is critical for the onset of proliferation. A recent study used commensal *C. perfringens*, the isolate from normal chicken, to challenge broiler and reproduce NE in conjunction with infection of *E. maxima* [64]. This result also highlighted that not the specific *C. perfringens* strain but the exogenous addition of *C. perfringens* played the key in achieving the consequence. Accordingly, the methodology to inhibit overgrowth of *Clostridium sensu stricto* 1 or *C. perfringens* in small intestines will be the straightforward strategy to prevent NE.

Recent studies have been shown that cecal microbiota had a prominent role in feed efficiency [65] and received increasing attention in terms of diseases [66] and metabolism [67]. In this study, the result of PCoA and PCA demonstrated that microbial communities in the jejunum were different from those in the cecum. Side by side treatments of *C. perfringens* and *Eimeria* promoted microbial shifts with biological significance in the jejunum but minimal fluctuations in taxa abundance in the cecum. Comparatively, jejunal microbiota was more significant than cecal microbiota to address characteristic gut microbiota contributory to NE by means of metagenomeSeq and LEfSe analysis. The reason might be that cecal microbiota is demonstrated more diverse than other intestinal sections [68] and inhibits higher amounts of microbes (10^{10} - 10^{11} CFU/g) than those in the jejunum (10^8 - 10^9 CFU/g) [69]. Those may provide the buffer effect on microbial changes in cecal microbiota. Besides, preferential colonization of *C.*

perfringens on mucosa of the small intestine [33] may also contribute to less amount of *C.*

perfringens into cecum, hence adverse to elicit significant changes in cecal microbiota.

Medium-chain fatty acids (MCFAs) such as lauric acid are a family of saturated 6- to 12-carbon fatty acids from plants and documented beneficial effects on intestinal health and microbial growth inhibition [70-72]. The mechanism for their bactericidal activity is not fully understood. Relative studies showed that they could act as nonionic surfactants to become incorporated into the bacterial cell membrane, as well as diffuse through cell membranes and create pores, changing membrane permeability and leading to cell death [73-75]. In this work, lauric acid attracted interest due to its inexpensiveness and natural properties, including strong antibacterial effects against *C. perfringens* and no inhibitory effect on *Eimeria* infection [76].

Based on Timbermont's study, lauric acid was most effective in inhibiting the growth of *C. perfringens* strain *in vitro*. Given a supplementary dose of 0.4 kg/ton in feed caused a significant decrease in NE incidence (from 50% down to 25%) compared with the infected, untreated control group [29]. This study followed the dose and used experimental grade product of lauric acid to evaluate the effects on NE incidence and intestinal microbiota. However, the addition of lauric acid did not reduce the incidence of NE. For intestinal microbiota, lauric acid neither exerted the inhibitory effect against proliferation of *C. perfringens* nor elevated the level of beneficial bacteria, such as *Lactobacillus* and *Bifidobacterium*. But, the relative abundance of *Escherichia Shigella* was decreased without affecting the incidence. Since lauric acid has different grade of products, such as experimental or food grade, the contradictory result may attribute to the influence of different formula on the absorptive efficiency of this compound. MCFAs are hydrophobic and partly absorbed through the stomach mucosa. Hence, their

triacylglycerols are considered as a desirable formula for feed additive because they can be absorbed intact into intestinal epithelial enterocytes via this form [77].

In summary, significant overgrowth of *Clostridium sensu stricto 1* in jejunum was recognized as the major microbiota contributory to NE. In addition to *C. perfringens*, other member within *Clostridium sensu stricto 1* was also found to participate in disease development. The decrement of *Lactobacillus* following the NE severity indicated that lactobacilli also participate in the progress of disease. These taxa showed counteractive effects in their functions as well as in the bacterial abundance, attempting to maintain the homeostasis of jejunal microbiota in chickens. Therefore, manipulations to inhibit multiplication of *Clostridium sensu stricto 1* and *C. perfringens* and to rehabilitate the dominant *Lactobacillus* population in the jejunum should be the niche for developing effective strategies to prevent NE.

Acknowledgments

The authors would like to thank Dr. John F. Prescott (University of Guelph, Ontario, Canada) for providing *netB* positive *C. perfringens* strain CP1. This work was supported by the USDA, National Institute of Food and Agriculture (CRIS Project Accession Number 1014508) and the College of Veterinary Medicine, Mississippi State University.

References

1. Cooper KK, Songer JG, Uzal FA. Diagnosing clostridial enteric disease in poultry. J Vet Diagn Invest. 2013;25(3):314-27. doi: 10.1177/1040638713483468. PubMed PMID: 23572451.

2. Martin TG, Smyth JA. Prevalence of netB among some clinical isolates of *Clostridium perfringens* from animals in the United States. *Vet Microbiol.* 2009;136(1-2):202-5. Epub 2008/12/17. doi: 10.1016/j.vetmic.2008.10.026. PubMed PMID: 19081686.
3. Van Der Sluis W. Clostridial enteritis is an often underestimated problem. *World poultry.* 2000;16(7):42-3.
4. Wade B, Keyburn. A. The true cost of necrotic enteritis. *World Poultry.* 2015; 31:16–7.
5. Liu D, Guo Y, Wang Z, Yuan J. Exogenous lysozyme influences *Clostridium perfringens* colonization and intestinal barrier function in broiler chickens. *Avian Pathol.* 2010;39(1):17-24. Epub 2010/04/15. doi: 10.1080/03079450903447404. PubMed PMID: 20390532.
6. Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. *Clin Microbiol Rev.* 2011;24(4):718-33. doi: 10.1128/CMR.00002-11. PubMed PMID: 21976606; PubMed Central PMCID: PMC3194830.
7. Van Immerseel F, De Buck J, Pasmans F, Huyghebaert G, Haesebrouck F, Ducatelle R. *Clostridium perfringens* in poultry: an emerging threat for animal and public health. *Avian Pathol.* 2004;33(6):537-49. Epub 2005/03/15. doi: 10.1080/03079450400013162. PubMed PMID: 15763720.
8. Van Immerseel F, Rood JI, Moore RJ, Titball RW. Rethinking our understanding of the pathogenesis of necrotic enteritis in chickens. *Trends Microbiol.* 2009;17(1):32-6. Epub 2008/11/04. doi: 10.1016/j.tim.2008.09.005. PubMed PMID: 18977143.
9. Casewell M, Friis C, Marco E, McMullin P, Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. *J*

- Antimicrob Chemother. 2003;52(2):159-61. Epub 2003/07/03. doi: 10.1093/jac/dkg313.
PubMed PMID: 12837737.
10. Timbermont L, Haesebrouck F, Ducatelle R, Van Immerseel F. Necrotic enteritis in
broilers: an updated review on the pathogenesis. Avian Pathol. 2011;40(4):341-7. Epub
2011/08/05. doi: 10.1080/03079457.2011.590967. PubMed PMID: 21812711.
11. Gaucher ML, Quessy S, Letellier A, Arsenault J, Boulianne M. Impact of a drug-free
program on broiler chicken growth performances, gut health, *Clostridium perfringens* and
Campylobacter jejuni occurrences at the farm level. Poult Sci. 2015;94(8):1791-801. Epub
2015/06/07. doi: 10.3382/ps/pev142. PubMed PMID: 26047674.
12. Rehman HU, Vahjen W, Awad WA, Zentek J. Indigenous bacteria and bacterial metabolic
products in the gastrointestinal tract of broiler chickens. Arch Anim Nutr. 2007;61(5):319-
35. Epub 2007/11/23. doi: 10.1080/17450390701556817. PubMed PMID: 18030916.
13. Pan D, Yu Z. Intestinal microbiome of poultry and its interaction with host and diet. Gut
Microbes. 2014;5(1):108-19. doi: 10.4161/gmic.26945. PubMed PMID: 24256702;
PubMed Central PMCID: PMC4049927.
14. Yin Y, Lei F, Zhu L, Li S, Wu Z, Zhang R, et al. Exposure of different bacterial inocula to
newborn chicken affects gut microbiota development and ileum gene expression. ISME J.
2010;4(3):367-76. doi: 10.1038/ismej.2009.128. PubMed PMID: 19956274.
15. Mwangi WN, Beal RK, Powers C, Wu X, Humphrey T, Watson M, et al. Regional and
global changes in TCRalpha T cell repertoires in the gut are dependent upon the
complexity of the enteric microflora. Dev Comp Immunol. 2010;34(4):406-17. doi:
10.1016/j.dci.2009.11.009. PubMed PMID: 19945480.

16. Crhanova M, Hradecka H, Faldynova M, Matulova M, Havlickova H, Sisak F, et al.
Immune response of chicken gut to natural colonization by gut microflora and to
Salmonella enterica serovar enteritidis infection. Infect Immun. 2011;79(7):2755-63. doi:
10.1128/IAI.01375-10. PubMed PMID: 21555397; PubMed Central PMCID:
PMCPMC3191970.
17. Feng Y, Gong J, Yu H, Jin Y, Zhu J, Han Y. Identification of changes in the composition
of ileal bacterial microbiota of broiler chickens infected with Clostridium perfringens. Vet
Microbiol. 2010;140(1-2):116-21. doi: 10.1016/j.vetmic.2009.07.001. PubMed PMID:
19647376.
18. Stanley D, Keyburn AL, Denman SE, Moore RJ. Changes in the caecal microflora of
chickens following Clostridium perfringens challenge to induce necrotic enteritis. Vet
Microbiol. 2012;159(1-2):155-62. Epub 2012/04/11. doi: 10.1016/j.vetmic.2012.03.032.
PubMed PMID: 22487456.
19. Stanley D, Wu SB, Rodgers N, Swick RA, Moore RJ. Differential responses of cecal
microbiota to fishmeal, Eimeria and Clostridium perfringens in a necrotic enteritis
challenge model in chickens. PLoS One. 2014;9(8):e104739. doi:
10.1371/journal.pone.0104739. PubMed PMID: 25167074; PubMed Central PMCID:
PMCPMC4148237.
20. Li Z, Wang W, Liu D, Guo Y. Effects of Lactobacillus acidophilus on gut microbiota
composition in broilers challenged with Clostridium perfringens. PLoS One.
2017;12(11):e0188634. doi: 10.1371/journal.pone.0188634. PubMed PMID: 29190649;
PubMed Central PMCID: PMCPMC5708699.

21. Dittmar E, Beyer P, Fischer D, Schafer V, Schoepe H, Bauer K, et al. Necrotizing enterocolitis of the neonate with *Clostridium perfringens*: diagnosis, clinical course, and role of alpha toxin. *Eur J Pediatr*. 2008;167(8):891-5. doi: 10.1007/s00431-007-0614-9. PubMed PMID: 17952466.
22. Heida FH, van Zoonen AG, Hulscher JB, te Kieft BJ, Wessels R, Kooi EM, et al. A Necrotizing Enterocolitis-Associated Gut Microbiota Is Present in the Meconium: Results of a Prospective Study. *Clin Infect Dis*. 2016;62(7):863-70. Epub 2016/01/21. doi: 10.1093/cid/ciw016. PubMed PMID: 26787171.
23. Dahiya JP, Wilkie DC, Van Kessel AG, Drew MD. Potential strategies for controlling necrotic enteritis in broiler chickens in post-antibiotic era. *Anim Feed Sci Technol*. 2006;129(1-2):60-88. doi: 10.1016/j.anifeedsci.2005.12.003.
24. Caly DL, D'Inca R, Auclair E, Drider D. Alternatives to Antibiotics to Prevent Necrotic Enteritis in Broiler Chickens: A Microbiologist's Perspective. *Front Microbiol*. 2015;6:1336. doi: 10.3389/fmicb.2015.01336. PubMed PMID: 26648920; PubMed Central PMCID: PMC4664614.
25. Hermans D, Martel A, Garmyn A, Verlinden M, Heyndrickx M, Gantois I, et al. Application of medium-chain fatty acids in drinking water increases *Campylobacter jejuni* colonization threshold in broiler chicks. *Poult Sci*. 2012;91(7):1733-8. doi: 10.3382/ps.2011-02106. PubMed PMID: 22700521.
26. Van Immerseel F, De Buck J, Boyen F, Bohez L, Pasmans F, Volf J, et al. Medium-chain fatty acids decrease colonization and invasion through *hilA* suppression shortly after infection of chickens with *Salmonella enterica* serovar Enteritidis. *Appl Environ*

- Microbiol. 2004;70(6):3582-7. doi: 10.1128/AEM.70.6.3582-3587.2004. PubMed PMID: 15184160; PubMed Central PMCID: PMCPMC427757.
27. Zeiger K, Popp J, Becker A, Hankel J, Visscher C, Klein G, et al. Lauric acid as feed additive - An approach to reducing *Campylobacter* spp. in broiler meat. PLoS One. 2017;12(4):e0175693. doi: 10.1371/journal.pone.0175693. PubMed PMID: 28419122; PubMed Central PMCID: PMCPMC5395180.
28. Skrivanova E, Marounek M, Dlouha G, Kanka J. Susceptibility of *Clostridium perfringens* to C-C fatty acids. Lett Appl Microbiol. 2005;41(1):77-81. doi: 10.1111/j.1472-765X.2005.01709.x. PubMed PMID: 15960756.
29. Timbermont L, Lanckriet A, Dewulf J, Nollet N, Schwarzer K, Haesebrouck F, et al. Control of *Clostridium perfringens*-induced necrotic enteritis in broilers by target-released butyric acid, fatty acids and essential oils. Avian Pathol. 2010;39(2):117-21. doi: 10.1080/03079451003610586. PubMed PMID: 20390546.
30. Wu SB, Stanley D, Rodgers N, Swick RA, Moore RJ. Two necrotic enteritis predisposing factors, dietary fishmeal and *Eimeria* infection, induce large changes in the caecal microbiota of broiler chickens. Vet Microbiol. 2014;169(3-4):188-97. doi: 10.1016/j.vetmic.2014.01.007. PubMed PMID: 24522272.
31. Prescott JF, Smyth JA, Shojadoost B, Vince A. Experimental reproduction of necrotic enteritis in chickens: a review. Avian Pathol. 2016;45(3):317-22. doi: 10.1080/03079457.2016.1141345. PubMed PMID: 26813025.
32. Shojadoost B, Vince AR, Prescott JF. The successful experimental induction of necrotic enteritis in chickens by *Clostridium perfringens*: a critical review. Vet Res. 2012;43:74.

- 662 Epub 2012/10/30. doi: 10.1186/1297-9716-43-74. PubMed PMID: 23101966; PubMed
663 Central PMCID: PMCPMC3546943.
- 664 33. Prescott JF, Parreira VR, Mehdizadeh Gohari I, Lepp D, Gong J. The pathogenesis of
665 necrotic enteritis in chickens: what we know and what we need to know: a review. Avian
666 Pathol. 2016;45(3):288-94. doi: 10.1080/03079457.2016.1139688. PubMed PMID:
667 26813023.
- 668 34. Moore RJ. Necrotic enteritis predisposing factors in broiler chickens. Avian Pathol.
669 2016;45(3):275-81. doi: 10.1080/03079457.2016.1150587. PubMed PMID: 26926926.
- 670 35. Xu S, Lin Y, Zeng D, Zhou M, Zeng Y, Wang H, et al. Bacillus licheniformis normalize
671 the ileum microbiota of chickens infected with necrotic enteritis. Sci Rep. 2018;8(1):1744.
672 doi: 10.1038/s41598-018-20059-z. PubMed PMID: 29379124; PubMed Central PMCID:
673 PMCPMC5789067.
- 674 36. Lin Y, Xu S, Zeng D, Ni X, Zhou M, Zeng Y, et al. Disruption in the cecal microbiota of
675 chickens challenged with Clostridium perfringens and other factors was alleviated by
676 Bacillus licheniformis supplementation. PLoS One. 2017;12(8):e0182426. doi:
677 10.1371/journal.pone.0182426. PubMed PMID: 28771569; PubMed Central PMCID:
678 PMCPMC5542615.
- 679 37. Branton SL, Reece FN, Hagler WM, Jr. Influence of a wheat diet on mortality of broiler
680 chickens associated with necrotic enteritis. Poult Sci. 1987;66(8):1326-30. Epub
681 1987/08/01. PubMed PMID: 2891128.
- 682 38. Thompson DR, Parreira VR, Kulkarni RR, Prescott JF. Live attenuated vaccine-based
683 control of necrotic enteritis of broiler chickens. Vet Microbiol. 2006;113(1-2):25-34. Epub
684 2005/11/18. doi: 10.1016/j.vetmic.2005.10.015. PubMed PMID: 16289639.

39. Jiang Y, Kulkarni RR, Parreira VR, Prescott JF. Immunization of broiler chickens against *Clostridium perfringens*-induced necrotic enteritis using purified recombinant immunogenic proteins. *Avian Dis.* 2009;53(3):409-15. Epub 2009/10/24. doi: 10.1637/8656-021109-Reg.1. PubMed PMID: 19848081.
40. Yu Q, Lepp D, Mehdizadeh Gohari I, Wu T, Zhou H, Yin X, et al. The Agr-like quorum sensing system is required for necrotic enteritis pathogenesis in poultry caused by *Clostridium perfringens*. *Infect Immun.* 2017. Epub 2017/04/05. doi: 10.1128/iai.00975-16. PubMed PMID: 28373356.
41. Zhou H, Lepp D, Pei Y, Liu M, Yin X, Ma R, et al. Influence of pCP1NetB ancillary genes on the virulence of *Clostridium perfringens* poultry necrotic enteritis strain CP1. *Gut Pathog.* 2017;9:6. doi: 10.1186/s13099-016-0152-y. PubMed PMID: 28127404; PubMed Central PMCID: PMC5251324.
42. Keyburn AL, Sheedy SA, Ford ME, Williamson MM, Awad MM, Rood JI, et al. Alpha-toxin of *Clostridium perfringens* is not an essential virulence factor in necrotic enteritis in chickens. *Infect Immun.* 2006;74(11):6496-500. Epub 2006/08/23. doi: 10.1128/iai.00806-06. PubMed PMID: 16923791; PubMed Central PMCID: PMC1695520.
43. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics.* 2011;27(21):2957-63. doi: 10.1093/bioinformatics/btr507. PubMed PMID: 21903629; PubMed Central PMCID: PMC3198573.
44. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods.* 2010;7(5):335-6. doi: 10.1038/nmeth.f.303. PubMed PMID: 20383131; PubMed Central PMCID: PMC3156573.

45. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics*. 2011;27(16):2194-200. doi: 10.1093/bioinformatics/btr381. PubMed PMID: 21700674; PubMed Central PMCID: PMC3150044.
46. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*. 2010;26(19):2460-1. doi: 10.1093/bioinformatics/btq461. PubMed PMID: 20709691.
47. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nat Methods*. 2013;10(10):996-8. Epub 2013/08/21. doi: 10.1038/nmeth.2604. PubMed PMID: 23955772.
48. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol*. 2007;73(16):5261-7. doi: 10.1128/AEM.00062-07. PubMed PMID: 17586664; PubMed Central PMCID: PMC1950982.
49. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics*. 2014;30(21):3123-4. doi: 10.1093/bioinformatics/btu494. PubMed PMID: 25061070; PubMed Central PMCID: PMC4609014.
50. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. *Genome Biol*. 2011;12(6):R60. doi: 10.1186/gb-2011-12-6-r60. PubMed PMID: 21702898; PubMed Central PMCID: PMC3218848.
51. Antonissen G, Eeckhaut V, Van Driessche K, Onrust L, Haesebrouck F, Ducatelle R, et al. Microbial shifts associated with necrotic enteritis. *Avian Pathol*. 2016;45(3):308-12. doi: 10.1080/03079457.2016.1152625. PubMed PMID: 26950294.

52. Sengupta R, Altermann E, Anderson RC, McNabb WC, Moughan PJ, Roy NC. The role of cell surface architecture of lactobacilli in host-microbe interactions in the gastrointestinal tract. *Mediators Inflamm.* 2013;2013:237921. Epub 2013/04/12. doi: 10.1155/2013/237921. PubMed PMID: 23576850; PubMed Central PMCID: PMC3610365.
53. Belenguer A, Duncan SH, Holtrop G, Anderson SE, Lobley GE, Flint HJ. Impact of pH on lactate formation and utilization by human fecal microbial communities. *Appl Environ Microbiol.* 2007;73(20):6526-33. doi: 10.1128/AEM.00508-07. PubMed PMID: 17766450; PubMed Central PMCID: PMC2075063.
54. Mora A, Herrera A, Mamani R, Lopez C, Alonso MP, Blanco JE, et al. Recent emergence of clonal group O25b:K1:H4-B2-ST131 *ibeA* strains among *Escherichia coli* poultry isolates, including CTX-M-9-producing strains, and comparison with clinical human isolates. *Appl Environ Microbiol.* 2010;76(21):6991-7. doi: 10.1128/AEM.01112-10. PubMed PMID: 20817805; PubMed Central PMCID: PMC2976257.
55. Du E, Gan L, Li Z, Wang W, Liu D, Guo Y. In vitro antibacterial activity of thymol and carvacrol and their effects on broiler chickens challenged with *Clostridium perfringens*. *J Anim Sci Biotechnol.* 2015;6:58. doi: 10.1186/s40104-015-0055-7. PubMed PMID: 26705471; PubMed Central PMCID: PMC4690362.
56. Du E, Wang W, Gan L, Li Z, Guo S, Guo Y. Effects of thymol and carvacrol supplementation on intestinal integrity and immune responses of broiler chickens challenged with *Clostridium perfringens*. *J Anim Sci Biotechnol.* 2016;7:19. doi: 10.1186/s40104-016-0079-7. PubMed PMID: 27006768; PubMed Central PMCID: PMC4802587.

57. Fusco V, Quero GM, Cho GS, Kabisch J, Meske D, Neve H, et al. The genus *Weissella*: taxonomy, ecology and biotechnological potential. *Front Microbiol.* 2015;6:155. doi: 10.3389/fmicb.2015.00155. PubMed PMID: 25852652; PubMed Central PMCID: PMC4362408.
58. Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal J, Garcia P, et al. The phylogeny of the genus *Clostridium*: proposal of five new genera and eleven new species combinations. *Int J Syst Bacteriol.* 1994;44(4):812-26. Epub 1994/10/01. doi: 10.1099/00207713-44-4-812. PubMed PMID: 7981107.
59. Stackebrandt E, Kramer I, Swiderski J, Hippe H. Phylogenetic basis for a taxonomic dissection of the genus *Clostridium*. *FEMS Immunol Med Microbiol.* 1999;24(3):253-8. Epub 1999/07/09. PubMed PMID: 10397308.
60. Rajilic-Stojanovic M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev.* 2014;38(5):996-1047. doi: 10.1111/1574-6976.12075. PubMed PMID: 24861948; PubMed Central PMCID: PMC4262072.
61. Lakshminarayanan B, Harris HM, Coakley M, O'Sullivan O, Stanton C, Pruteanu M, et al. Prevalence and characterization of *Clostridium perfringens* from the faecal microbiota of elderly Irish subjects. *J Med Microbiol.* 2013;62(Pt 3):457-66. Epub 2012/12/12. doi: 10.1099/jmm.0.052258-0. PubMed PMID: 23222860.
62. Williams RB, Marshall RN, La Ragione RM, Catchpole J. A new method for the experimental production of necrotic enteritis and its use for studies on the relationships between necrotic enteritis, coccidiosis and anticoccidial vaccination of chickens. *Parasitol*

- Res. 2003;90(1):19-26. Epub 2003/05/14. doi: 10.1007/s00436-002-0803-4. PubMed PMID: 12743800.
63. Williams RB. Intercurrent coccidiosis and necrotic enteritis of chickens: rational, integrated disease management by maintenance of gut integrity. Avian Pathol. 2005;34(3):159-80. Epub 2005/09/30. doi: 10.1080/03079450500112195. PubMed PMID: 16191699.
64. Li C, Lillehoj HS, Gadde UD, Ritter D, Oh S. Characterization of Clostridium perfringens Strains Isolated from Healthy and Necrotic Enteritis-Afflicted Broiler Chickens. Avian Dis. 2017;61(2):178-85. Epub 2017/07/01. doi: 10.1637/11507-093016-Reg.1. PubMed PMID: 28665720.
65. Yan W, Sun C, Yuan J, Yang N. Gut metagenomic analysis reveals prominent roles of Lactobacillus and cecal microbiota in chicken feed efficiency. Sci Rep. 2017;7:45308. doi: 10.1038/srep45308. PubMed PMID: 28349946.
66. Wohlgemuth S, Keller S, Kertscher R, Stadion M, Haller D, Kisling S, et al. Intestinal steroid profiles and microbiota composition in colitic mice. Gut Microbes. 2011;2(3):159-66. doi: 10.4161/gmic.2.3.16104. PubMed PMID: 21869607.
67. Stanley D, Denman SE, Hughes RJ, Geier MS, Crowley TM, Chen H, et al. Intestinal microbiota associated with differential feed conversion efficiency in chickens. Appl Microbiol Biotechnol. 2012;96(5):1361-9. Epub 2012/01/18. doi: 10.1007/s00253-011-3847-5. PubMed PMID: 22249719.
68. Xiao Y, Xiang Y, Zhou W, Chen J, Li K, Yang H. Microbial community mapping in intestinal tract of broiler chicken. Poult Sci. 2017;96(5):1387-93. doi: 10.3382/ps/pew372. PubMed PMID: 28339527.

69. Yeoman CJ, Chia N, Jeraldo P, Sipos M, Goldenfeld ND, White BA. The microbiome of the chicken gastrointestinal tract. *Anim Health Res Rev.* 2012;13(1):89-99. doi: 10.1017/S1466252312000138. PubMed PMID: 22853945.
70. Dierick N, Michiels J, Van Nevel C. Effect of medium chain fatty acids and benzoic acid, as alternatives for antibiotics, on growth and some gut parameters in piglets. *Commun Agric Appl Biol Sci.* 2004;69(2):187-90. Epub 2004/11/25. PubMed PMID: 15560218.
71. Bertevello PL, De Nardi L, Torrinhas RS, Logullo AF, Waitzberg DL. Partial replacement of omega-6 fatty acids with medium-chain triglycerides, but not olive oil, improves colon cytokine response and damage in experimental colitis. *JPEN J Parenter Enteral Nutr.* 2012;36(4):442-8. Epub 2012/01/25. doi: 10.1177/0148607111421788. PubMed PMID: 22269895.
72. Zentek J, Buchheit-Renko S, Manner K, Pieper R, Vahjen W. Intestinal concentrations of free and encapsulated dietary medium-chain fatty acids and effects on gastric microbial ecology and bacterial metabolic products in the digestive tract of piglets. *Arch Anim Nutr.* 2012;66(1):14-26. Epub 2012/03/09. PubMed PMID: 22397093.
73. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. *Appl Microbiol Biotechnol.* 2010;85(6):1629-42. doi: 10.1007/s00253-009-2355-3. PubMed PMID: 19956944.
74. Altieri C, Bevilacqua A, Cardillo D, Sinigaglia M. Effectiveness of fatty acids and their monoglycerides against gram-negative pathogens. *Int J Food Sci Tech.* 2009;44(2):359-66. doi: 10.1111/j.1365-2621.2008.01744.x.

75. Bergsson G, Arnfinnsson J, Steingrimsen O, Thormar H. Killing of Gram-positive cocci by fatty acids and monoglycerides. APMIS. 2001;109(10):670-8. Epub 2002/03/14. PubMed PMID: 11890570.
76. Mathis G, T. P. van Dam J, Corujo Fernández A, L. Hofacre C. Effect of an organic acids and medium-chain fatty acids containing product in feed on the course of artificial Necrotic Enteritis infection in broiler chickens2018.
77. Zentek J, Buchheit-Renko S, Ferrara F, Vahjen W, Van Kessel AG, Pieper R. Nutritional and physiological role of medium-chain triglycerides and medium-chain fatty acids in piglets. Anim Health Res Rev. 2011;12(1):83-93. doi: 10.1017/S1466252311000089. PubMed PMID: 21676342.

Supporting information

Figure S1. Rarefaction curve by groups.

Figure S2. Comparison of genera abundance between jejunal and cecal microbiota by STAMP with Welch's t-test.

Figure S3. Rank abundance curve by groups.

Figure S4. Comparison of genera (A) and species (B) abundance between AJ and EJ, BJ and EJ, and CJ and EJ groups by STAMP with Welch's t-test.